Plerixafor
- Generic Name
- Plerixafor
- Brand Names
- Mozobil, Plerixafor Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C28H54N8
- CAS Number
- 110078-46-1
- Unique Ingredient Identifier
- S915P5499N
- Background
Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer. It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune system. These stem cells are then collected and...
- Indication
Plerixafor is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma.
- Associated Conditions
- -
- Associated Therapies
- Mobilization of hematopoietic stem cells
To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 2
- Registration Number
- NCT03277209
- Locations
- 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
🇺🇸Weill Cornell Medical College, New York, New York, United States
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT03240861
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2023-09-21
- Target Recruit Count
- 15
- Registration Number
- NCT03226691
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)
- Conditions
- Interventions
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 22
- Registration Number
- NCT03182426
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A
- Conditions
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2024-03-21
- Target Recruit Count
- 9
- Registration Number
- NCT03157804
- Locations
- 🇪🇸
Hospital Infantil del Niño Jesus, Madrid, Spain
🇪🇸Hospital Vall d'Hebron, Barcelona, Spain
Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Alessandra Biffi
- Target Recruit Count
- 6
- Registration Number
- NCT02989701
- Locations
- 🇺🇸
Boston Childrens Hospital, Boston, Massachusetts, United States
Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1
- First Posted Date
- 2016-10-12
- Last Posted Date
- 2020-05-27
- Target Recruit Count
- 13
- Registration Number
- NCT02931071
- Locations
- 🇪🇸
Hospital Infantil Universitario Niño Jesus, Madrid, Spain
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
Plerixafor in Diabetic Wound Healing
- Conditions
- Interventions
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2019-12-19
- Lead Sponsor
- Gian Paolo Fadini
- Target Recruit Count
- 25
- Registration Number
- NCT02790957
- Locations
- 🇮🇹
University Hospital of Padova, Padova, Italy
Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
- Conditions
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT02682953
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 4
- Registration Number
- NCT02678533
- Locations
- 🇫🇷
Hôpital necker-Enfants malades, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.